Making America Healthy Again → NOT
Biotech companies developing drugs for hard-to-treat diseases and other ailments are being forced to push back clinical trials and drug testing in the wake of mass layoffs at the Food and Drug Administration.
Significant delays in the FDA’s core functions—such as approving amendments to clinical trials and guiding companies through processes for drug approval—are hindering the ability to develop drugs, say industry officials. Those setbacks are contributing to drugs taking longer to get through clinical trials and ultimately reach patients—and straining dollars for testing new possible treatments, say people familiar with the matter.